As part of the U.S. Food and Drug Administration’s approval

As part of the U.S. Food and Drug Administration’s approval process, a new rheumatoid arthritis drug was compared to a placebo. The randomized, double-anonymous study with 482 patients showed that 41% of those given the new drug had a decrease in symptoms, while 19% of those given the placebo experienced improvement (Western Journal of Medicine). Which patients were in the treatment group and the control group? Do the results appear to offer evidence that the new drug was effective? Why or why not? Do the results appear to indicate that a placebo effect was present in this study? Explain. If you were on the panel deciding whether to approve the new drug, how would you vote based on this study? Explain your reasoning.

******CLICK ORDER NOW BELOW AND OUR WRITERS WILL WRITE AN ANSWER TO THIS ASSIGNMENT OR ANY OTHER ASSIGNMENT, DISCUSSION, ESSAY, HOMEWORK OR QUESTION YOU MAY HAVE. OUR PAPERS ARE PLAGIARISM FREE*******."